In a special report published by Malcovati et al in the journal Blood, an international working group of experts in myelodysplastic syndromes (MDS) has proposed the recognition of a distinct subtype of MDS based on the presence of a nonheritable genetic mutation that causes the disease. The mutation is found in approximately one in every five patients with MDS.
“This study represents an important step forward in the ability to diagnose MDS on the basis of genetic features, and this is paving the way to obtain a diagnosis without the need to analyze bone marrow,” said lead author Luca Malcovati, MD, of the University of Pavia Medical School in Italy, in an American Society of Hematology press release. “Patients who carry this genetic variant may benefit from treatment with an approved drug, luspatercept. In addition, other potential new treatments that directly target this genetic mutation are in the early stages of development and may benefit patients in the future.”
The mutation, known as SF3B1, is the most common genetic variant found in patients with MDS, said Dr. Malcovati. Patients with MDS who carry this genetic variant tend to have a less severe or aggressive form of the disease. Moreover, results from a result trial published by Feneaux et al in The New England Journal of Medicine showed that a high proportion of patients with MDS who carried the SF3B1 mutation responded to treatment with luspatercept, which was approved by the U.S. Food and Drug Administration in November 2019 to treat anemia in patients with beta thalassemia who require regular red blood cell transfusions.
A major strength of this proposal, said Dr. Malcovati, is that it has been developed and is supported by an international working group of experts who represent all of the major institutions worldwide that diagnose and treat MDS.
Selecting the best treatment for MDS depends on identifying the patient’s specific subtype of the disease. This is often difficult to do, however, since the diagnosis generally relies on examining bone marrow microscopically to identify abnormalities. With the change that the expert group is proposing, patients with MDS who carry the SF3B1 mutation will be able to get a definitive classification by means of a simple test.
A common feature of SF3B1-mutated MDS is ring sideroblasts. They develop as a result of the mutation’s interference with the blood cells’ use of iron, explained Dr. Malcovati. This interference impairs the cells’ capacity to produce hemoglobin, and this chain of events results in anemia—a primary symptom in patients with SF3B1-mutated MDS.
In this study, Dr. Malcovati and his colleagues analyzed the results of several previous studies that they say support the hypothesis that SF3B1-mutated MDS is a distinct subtype of the disease. They also examined records from a large international database of patients with MDS, in which 795 patients carried the SF3B1 mutation and 2,684 did not. The researchers concluded that SF3B1-mutated MDS has three main distinctive features: ineffective production of red blood cells, a relatively good prognosis, and a likelihood that patients’ anemia will improve when treated with the drug luspatercept.
In the report by Feneaux et al in The New England Journal of Medicine, luspatercept reduced anemia severity in patients with MDS with ring sideroblasts who had not responded to or could not tolerate treatment with drugs that stimulated the production of red blood cells. Of the patients treated with luspatercept, 93% carried the SF3B1 mutation.
The team also identified a number of other genetic variants that may occur in MDS in addition to the SF3B1 mutation. The presence of these additional mutations may signify more aggressive forms of the disease, said Dr. Malcovati. MDS with these additional genetic features would be excluded from the proposed new subtype of SF3B1-mutated disease, he said.
The study authors concluded, “Diagnosis of SF3B1-mutant MDS has considerable clinical implications in terms of risk stratification and therapeutic decision making. In fact, this condition has a relatively good prognosis and may respond to luspatercept with abolishment of transfusion requirement.”
Disclosure: For full disclosures of the study authors, visit ashpublications.org/blood.The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.